JNJ 64304500

Drug Profile

JNJ 64304500

Alternative Names: JNJ 64304500 AAA; JNJ-64304500

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Janssen
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease

Most Recent Events

  • 21 Dec 2016 Janssen Pharmaceutical plans a phase I trial in Healthy volunteers in Japan (SC) (NCT03002025).
  • 11 Nov 2016 Phase-II clinical trials in Crohn's disease in Hungary (SC) (EudraCT2016-000634-21)
  • 05 Aug 2016 Janssen plans a phase II trial for Crohn's disease in United Kingdom (NCT02877134, UKCRN30718)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top